ArticleBiomolecules2019
Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis.
Open access · goldAbstract read
In one paragraph
Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Effectiveness of Cerium Oxide Nanoparticles in Non-Alcoholic Fatty Liver Disease Evolution Using In Vivo and In Vitro Studies: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Targeting Stearoyl-CoA Desaturase‑1 (SCD1) by the Drug-Nutraceutical Combination of Montelukast and Bixin in Ameliorating Steatotic NAFLD.ACS omega · 2025Article
- Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights.Liver research (Beijing, China) · 2025Review
- Ultrasound-mediated nanomaterials for the treatment of inflammatory diseases.Ultrasonics sonochemistry · 2025Review
- Alcohol promotes CPT1A-induced lipid metabolism disorder to sentinel-regulate acute pancreatitis.European journal of medical research · 2025Article
- Therapeutic Nanomaterials in NAFLD: Current Advances and Potential Applications in Patients with Concurrent HBV Infection.International journal of nanomedicine · 2025Review
- New approaches to the treatment of metabolic dysfunction-associated steatotic liver with natural products.iLIVER · 2024Review
- Editorial: Advanced functional nanomaterials for diagnosis, bioimaging, drug delivery and therapeutics.Frontiers in molecular biosciences · 2024Article
- Facile aqueous synthesis and comparative evaluation of TiORSC advances · 2023Article
- Modified Titanium Dioxide as a Potential Visible-Light-Activated Photosensitizer for Bladder Cancer Treatment.ACS omega · 2022Article
- Understanding Nanomaterial-Liver Interactions to Facilitate the Development of Safer Nanoapplications.Advanced materials (Deerfield Beach, Fla.) · 2022Review
- Magnetic Mesoporous Silica Nanorods Loaded with Ceria and Functionalized with Fluorophores for Multimodal Imaging.ACS applied nano materials · 2022Article
- The Interactions between Nanoparticles and the Innate Immune System from a Nanotechnologist Perspective.Nanomaterials (Basel, Switzerland) · 2021Review
- Validation of a Gas Chromatography-Mass Spectrometry Method for the Measurement of the Redox State Metabolic Ratios Lactate/Pyruvate and β-Hydroxybutyrate/Acetoacetate in Biological Samples.International journal of molecular sciences · 2021Article
- Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review.Bioinorganic chemistry and applications · 2021Review
- Knockout of theInternational journal of molecular sciences · 2020Article
- Hydrogen Sulfide Attenuates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease by Inhibiting Apoptosis and Promoting Autophagy via Reactive Oxygen Species/Phosphatidylinositol 3-Kinase/AKT/Mammalian Target of Rapamycin Signaling Pathway.Frontiers in pharmacology · 2020Article
- Can tailored nanoceria act as a prebiotic? Report on improved lipid profile and gut microbiota in obese mice.The EPMA journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Marina Parra-RobertService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain.
Eudald CasalsSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.ORCID 0000-0002-2900-7295
Nuria MassanaService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain.ORCID 0000-0002-5403-3161
Muling ZengSchool of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China.
Meritxell PerramónService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain.ORCID 0000-0002-1944-8337
Guillermo Fernández-VaroService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain.
Manuel Morales-RuizService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain.
Víctor PuntesVall d'Hebron Research Institute (VHIR), 08035 Barcelona, Spain.
Wladimiro JiménezService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain.ORCID 0000-0002-9376-0214
Gregori CasalsService of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08905 Barcelona, Spain. casals@clinic.cat.ORCID 0000-0002-3271-1371
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESWuyi University · CNInstitució Catalana de Recerca i Estudis Avançats · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic accumulation of lipids. Antisteatotic effects of cerium oxide nanoparticles (CeO
Indexed as
Carcinoma, HepatocellularCell SurvivalCeriumFatty Acid DesaturasesFatty Acid ElongasesFatty AcidsHep G2 CellsHumansHydrogen PeroxideLiver NeoplasmsMetal NanoparticlesOxidative StressPalmitic AcidReactive Oxygen SpeciesSpectrometry, FluorescenceStearic Acidsceric oxideCeriumFatty Acid DesaturasesFatty Acid ElongasesFatty AcidsHydrogen PeroxidePalmitic AcidReactive Oxygen Speciesstearic acidStearic Acidscerium oxide nanoparticleslivernonalcoholic fatty liver diseaseoxidative stresssteatosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.